Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 16/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.47 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876133 | 0.86 | BRAF (0.46) | SLC22A12PIK3CAPTPN2PTPN1PTPN5 | |
| SCHEMBL4878313 | 0.84 | SLC22A12 (0.46) | SLC22A12PIK3CAPTPN2PTPN1PTPN5 | |
| SCHEMBL4879404 | 0.81 | TSHR (0.52) | PTPN2PTPN1PTPN5 | |
| SCHEMBL4875769 | 0.81 | HTR6 (0.53) | PIK3CA | |
| SCHEMBL4878244 | 0.81 | SGK1 (0.46) | CYP3A4 | |
| SCHEMBL14164305 | 0.81 | SLC22A12 (0.55) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL4878331 | 0.80 | KIT (0.46) | PIK3CA | |
| SCHEMBL4879656 | 0.78 | L3MBTL1 (0.47) | — | |
| SCHEMBL4875782 | 0.78 | CA12 (0.48) | PIK3CAPTPN2PTPN1PTPN5 | |
| SCHEMBL4718548 | 0.77 | AURKB (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| CN-101151261-A | Pyrimidine compounds having tie2 (TEK) inhibitory activity | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | TIE1, TEK, KDR | SLC22A12 2993/4885CYP2C9 2718/4885SLC22A6 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.